Regulatory cytokines in the response to allogeneic renal transplant;Citoquinas reguladoras de la respuesta al trasplante renal alogenico

Medicina

Volumn 65, Issue 1, 2005, Pages 54-62

  Cardoni, Rita L ^a   Prigoshin, Norma ^a   Tambutti, Monica L ^a   Ferraris, Jorge R ^a  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

Cytokines; Inflammation; Kidney; Th1; Th2; Transplant

Indexed keywords

CYTOKINE; INTERLEUKIN 10; LYMPHOTOXIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ARTICLE; COST EFFECTIVENESS ANALYSIS; CYTOKINE PRODUCTION; CYTOTOXICITY; DIAGNOSTIC PROCEDURE; EARLY DIAGNOSIS; FIBROGENESIS; GRAFT SURVIVAL; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSTIMULATION; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY INJURY; KIDNEY TRANSPLANTATION; PROTEIN FUNCTION; SENSITIVITY ANALYSIS; TH1 CELL;

AUTOIMMUNITY; BIOLOGICAL MARKERS; CYTOKINES; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 17144426444     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Pascual M, Theruvath T, Kawai T, Tokoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580-90.
2. Jain S, Furness PN, Nicholson ML. The role of transforming growth factor beta in chronic renal allograft nephropathy. Overview. Transplantation 2000; 69: 1759-66.
3. Janeway CA, Travers P, Walport M, Shlomchik M. Immunobiolgy. The immune system in health and disease. 5th ed. New York: Garland Publishing, 2001.
4. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunology Today 1996; 17: 138-46.
5. Annunziato F, Cosmi L, Galli G, et al. Assessment of chemokine receptor expression by human Th1 and Th2 cells in vitro and in vivo. J Leukoc Biol 1999; 65: 691-9.
6. Gould DS, Auchincloss Jr H. Direct and indirect recognition: the role of MHC antigens in graft rejection. Immunol Today 1999; 20: 77-82.
7. Strehlau J, Pavlakis M, Lipman M, et al. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci USA 1997; 94: 695-700.
8. Baker RJ, Hernández Fuentes MP, Brookes PA, et al. Loss of direct and maintenance of indirect alloresponses in renal allograft recipients: implications for the pathogenesis of chronic allograft nephropathy. J Immunol 2001; 167: 7199-206.
9. Pratschke J, Wilhelm MJ, Kusaka M, et al. Accelerated rejection of renal allograft from brain-dead donors. Ann Surg 2000; 232: 263-71.
10. Dallman MJ. Cytokines and transplantation. Th1/Th2 regulation of the immune response to solid organ transplants in the adult. Curr Opin Immunol 1995; 7: 632-8.
11. Zuo XJ, Jordan SC, Wilkinson A, et al. Interleukin-12 mRNA levels in renal allograft fine-needle aspirates do not correlate with acute transplant rejection. Transplantation 1995; 60: 1360-2.
12. Tary Lehmann M, Hricik DE, Justice AC, Potter NS, Heeger PS. Enzyme-linked immunosorbent assay spot detection of interferon-gamma and interleukin 5-producing cells as a predictive marker for renal allograft failure. Transplantation 1998; 66: 219-24.
13. Weiler M, Rogashew B, Einbinder T, et al. Interleukin-15, a leukocyte activator and growth factor, is produced by cortical tubular epithelial cells. J Am Soc Nephrol 1998; 9: 1194-201.
14. Li B, Hartono C, Ding R, et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001; 344: 947-54.
15. Waiser J, Budde K, Katalinic A, et al. Interleukin-6 expression after renal transplantation. Nephrol Dial Transplant 1997; 12: 753-9.
16. Sadeghi M, Daniel V, Wiesel M, Hergesell O, Opelz G. High urine sIL-6R as a predictor of late graft failure in renal transplant recipients. Transplantation 2003; 76: 1190-4.
17. Teppo AM, von Willebrand E, Honkanen E, Ahonen J, Gronhagen-Riska C. Soluble intercellular adhesion molecule-1 (sICAM-1) after kidney transplantation: the origin and role of urinary sICAM-1? Transplantation 2001; 71: 1113-9.
18. Pelzl S, Opelz G, Wiesel M, et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 2002; 73: 3-6.
19. Boratynska M. Urine excretion of transforming growth factor-beta1 in chronic allograft nephropathy. Ann Transplant 1999; 4: 23-8.
20. Eikmans M, Sijpkens YW, Baelde HJ, et al. High transforming growth factor-beta and extracellular matrix mRNA response in renal allografts during early acute rejection is associated with absence of chronic rejection. Transplantation 2002; 73: 573-9.
21. Van Buskirk AM, Burlingham WJ, Jankowska Gan E, et al. Human allograft acceptance is associated with immune regulation. J Clin Invest 2000, 106: 145-55.
22. Halloran PF, Miller LW, Urmson J, et al. IFN-gamma alters the pathology of grafts rejection: protection from early necrosis. J Immunol 2001; 166: 7072-81.
23. Bendelac A, Rivera MN, Park S, Roark JH. Mouse CD1-specific NK 1 T cells: development, specificity, and function. Annu Rev Immunol 1997; 15: 535-62.
24. Seino KI, Fukao K, Muramoto K, et al. Requirement for natural killer T (NKT) cells in the induction of allograft tolerance. Proc Natl Acad Sci USA 2001; 98: 2577-81.
25. Higuchi M, Zeng D, Shizuru J, et al. Immune tolerance to combined organ and bone marrow transplants after fractionated lymphoid irradiation involves regulatory NKT cells and clonal deletion. J Immunol 2002; 169: 5564-70.
26. Kaplanski G, Marin V, Montero JF, Mantovani A, Farnarier C. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol 2003; 24: 25-9.
27. Kaden J, Priesterjahn R. Increasing urinary IL-6 levels announce kidney graft rejection. Transpl Int 2000; 13 Suppl 1: S34-41.
28. Ode Hakim S, Docke WD, Kern F, et al. Delayed-type hypersensitivity-like mechanisms dominate late acute rejection episodes in renal allograft recipients. Transplantation 1996; 61: 1233-40.
29. Nordoy I, Muller F, Nordal KP, et al. Chemokines and soluble adhesion molecules in renal transplant recipients with cytomegalovirus infection. Clin Exp Immunol 2000; 120: 333-7.
30. Kern F, Ode hakim S, Nugel H, et al. Peripheral T cell activation in long-term renal transplant patients: concordant upregulation of adhesion molecules and cytokine gene transcription. J Am Soc Nephrol 1996; 7: 2476-82.
31. Nam SY, Cho KS, Heo YM, et al. Regulation of lymphocyte clustering by CD30-mediated ICAM-1 upregulation. Cell Immunol 2002; 219: 38-47.
32. Nakao K, Nagake Y, Okamoto A, et al. Serum levels of soluble CD26 and CD30 in patients on hemodialysis. Nephron 2002; 91: 215-21.
33. De Lazzari F, Ravagnan P, Tenderini M, et al. Circulating soluble-CD30 (sCD30) in patients with HCV-related chronic hepatitis and in patients with alcoholic liver disease. Hepatogastroenterology 2002; 49: 231-4.
34. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-55.
35. Timoshanko JR, Kitching AR, Holdsworth SR, Tipping PG. Interleukin-12 from intrinsic cells is an effector of renal injury in crescentic glomerulonephritis. J Am Soc Nephrol 2001; 12: 464-71.
36. Toyoda M, Galfayan K, Galera OA, et al. Cytomegalovirus infection induces anti-endothelial cell antibodies in cardiac and renal allograft recipients. Transpl Immunol 1997; 5: 104-11.
37. Fricke L, Kluter H, Feddersen A, et al. Preoperative application of glucocorticosteroids efficaciosuly reduces the primary immunological response in kidney transplantation. Clin Transplant 1996; 10: 432-6.
38. Ahuja SS, Shrivastav S, Danielpour D, Balow JE, Boumpas DT. Regulation of transforming growth factor-β1 and its receptor by cyclosporine in human T lymphocytes. Transplantation 1995; 60: 718-23.
39. Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit 1995; 17: 584-91.
40. Spencer CM, Goa KL, Gillis JC. Tracrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997; 54: 925-75.
41. Weimer R, Melk A, Daniel V, et al. Switch from cyclosporine A to tacrolimus in renal transplant recipients: impact on Th1, Th2, and monokine responses. Hum Immunol 2000; 61: 884-97.
42. Ferraris JR, Tambutti ML, Cardoni RL, Prigoshin N. Conversion from cyclosporine to tacrolimus in pediatric renal transplant recipients with chronic rejection: Changes in the immune response. Transplantation 2004; 77: 532-7.
43. Adams AB, Williams MA, Jones TR, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111: 1887-95.
44. Halloran PF, Homik J, Goes N, et al. The "injury response": a concept linking nonspecific injury, acute rejection, and long-term transplant outcomes. Transplant Proc 1997; 29: 79-81.
45. Fischereder M, Luckow B, Hocher B, et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001; 357: 1758-61.
46. Segerer S, Cui Y, Eitner F, et al. Expression of chemokines and chemokine receptors during human renal transplant rejection. Am J Kidney Dis 2001; 37: 518-31.
47. Song E, Zou H, Yao Y, et al. Early application of Met-RANTES ameliorates chronic allograft nephropathy. Kidney Int 2002; 61: 676-85.
48. Chakravorty SJ, Howie AJ, Girdlestone J, Gentle D, Savage CO. Potential role for monocyte chemotactic protein-4 (MCP-4) in monocyte/macrophage recruitment in acute renal inflammation. J Pathol 2001; 194: 239-46.
49. Kazmierski w, Bifulco N, Yang H, et al. Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors. Bioorg Med Chem 2003; 11: 2663-76.
50. Gregori S, Casorati M, Amuchastegui S, et al. Regulatory T cells induced by 1 alpha, 25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 2001; 167: 1945-53.
51. Kist van Holthe JE, Gasser M, Womer K, et al. Regulatory functions of alloreactive Th2 clones in human renal transplant recipients. Kidney Int 2002; 62: 627-31.
52. Nakagawa K, Matsuno T, Iwagaki H, Fujiwara T, Tanaka N. Analysis of the immune status in the recipients with long-term well- functioning kidneys allografts. Acta Med Okayama 2001; 55: 31-9.
53. Dinarello CA. Proinflammatory cytokines. Chest 2000; 118: 503-8.
54. Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM. The dual role of IL-10. Trend Immunol 2003; 24: 36-43.
55. Deng J, Kohda Y, Chiao H, et al. Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int 2001; 60: 2118-28.
56. Wissing KM, Morelon E, Legendre C, et al. A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy. Transplantation 1997; 64: 999-1006.
57. Lauw FN, Pajkrt D, Hack CE, et al. Proinflammatory effects of IL-10 during human endotoxemia. J Immunol 2000; 165: 2783-9.
58. + graft-infiltrating T lymphocytes in promptly rejected kidney allografts. Transplantation 1995; 59: 1113-9.
59. Aschenbrenner JK, Sollinger HW, Becker BN, Hullet DA. 1,25-(OH(2))D(3) alters the transforming growth factor beta signaling pathway in renal tissue. J Surg Res 2001; 100: 171-5.
60. Inigo P, Campistol JM, Lario S, et al. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta(1) plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol 2001; 12: 822-7.
61. Nakamura K, Kitani A, Strober W. Cell contact-dependent Immunosuppression by CD4(+)Cd25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001; 194: 629-44.
62. Hara M, Kingsley CI, Niimi M, et al. IL-10 is required for regulatory T cells to mediate tolerance to mediate tolerance to alloantigens in vivo. J Immunol 2001; 166: 3789-96.
63. - precursors. J Immunol 2002; 169: 4183-9.
64. Pascual M, Swinford RD, Ingelfinger JR, et al. Chronic rejection and chronic cyclosporin toxicity in renal allografts. Immunol Today 1998; 19: 514-9.
65. Coupes BM, Williams S, Roberts IS, Short CD, Brenchley PE. Plasma transforming growth factor beta (1) and platelet activation: implications for studies in transplant recipients. Nephrol Dial Transplant 2001; 16: 361-7.
66. Bickerstaff AA, Wang JJ, Pelletier RP, Orosz CG. Murine renal allografts: spontaneous acceptance is associated with regulated T cell-mediated immunity. J Immunol 2001; 167: 4821-7.
67. Thomson AW, Lu L. Are dendritic cells the key to liver transplant tolerance? Immunol Today 1999; 20: 27-32.
68. Ferraris JR, Duca P, Prigoshin N, et al. Mycophenolate mofetil and reduced doses of cyclosporine in pediatric liver transplantation with chronic renal dysfunction: Changes in the immune response. Pediatric Transp. 2004; 8: 16-21.
69. Poole KL, Gibbs PJ, Evans PR, Sadek SA, Howell WM. Influence of patients and donor cytokine genotypes on renal allograft rejection: evidence from a single centre study. Transpl Immunol 2001; 8: 259-65.
70. Asderakis A, Sankaran D, Dyer P, et al. Association of polymorphisms in the human interferon-gamma and interleukin-10 gene with acute and chronic kidney transplant outcome: the cytokine effect on transplantation. Transplantation 2001; 71: 674-7.
71. Hahn AB, Kasten Jolly JC, Constantino DM, et al. TNF-alpha, IL-6, IFN-gamma and IL-10 gene expression polymorphisms and the IL-4 receptor alpha-chain variant Q576R: Effects on renal allograft outcome. Transplantation 2001; 72: 660-5.
72. van Besouw NM, Vaessen LM, Zuijderwijk JM, et al. The frequency of interferon-γ producing cells reflects alloreactivity against minor histocompatibility antigens. Transplantation 2003; 75: 1400-4.